Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million 2024 expected Total Revenue.
Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million 2024 expected Total Revenue.
Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million
“Midcaps have rallied substantially, we need a growth of at least 10% or more for the industry for the overall stocks to do well because it is not an under-owned sector. Most funds own a significant amount of IT stocks despite the downturn. People who do not own, should start allocating. People who have reasonable exposure, should not go overweight right now.”
Grab Holdings: The Quest For Free Cash Flow Begins (NASDAQ:GRAB) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.